Karyopharm TherapeuticsKPTI
13F holders, Q2 2026 (June 30)1holders
0new positions
0sold out
$9.77avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Karyopharm Therapeutics Inc. (KPTI) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holder was Birchview Capital, LP ($420K).
- Company
- Karyopharm Therapeutics Inc.
- CUSIP
- 48576U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 41,000 shares sold, net −41,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Birchview Capital, LP | 0.20% | Reduce -48.8% | 42,952 | $420K |
"% of holder's portfolio" is KPTI's weight in each manager's 13F, not the share of Karyopharm Therapeutics Inc. the manager owns.